Objective:

To investigate the cellular diversity within the trabecular meshwork (TM) and identify potential therapeutic targets for glaucoma, emphasizing the significance of these targets.

Key Findings:

• Identified three distinct TM cell subtypes with unique gene expression profiles, with TM3 being particularly metabolically vulnerable and linked to mitochondrial dysfunction in glaucoma.
• TM3 subtype is metabolically vulnerable and linked to mitochondrial dysfunction in glaucoma, indicating a critical area for therapeutic intervention.
• Vitamin B3 (nicotinamide) supplementation prevents intraocular pressure elevation and mitigates glaucoma, suggesting a promising treatment strategy.

Interpretation:

TM3 cells, due to their high metabolic activity and vulnerability to stress, are critical in glaucoma progression. Nicotinamide enhances their resilience, suggesting a new therapeutic avenue that could be explored in clinical settings.

Limitations:

• Further research needed to confirm TM3 counterparts in human TM tissue, which is crucial for translating findings to clinical practice.
• Clinical studies required to establish safety and efficacy of nicotinamide in glaucoma treatment, ensuring its viability as a therapeutic option.

Conclusion:

Nicotinamide shows promise as a dual-action therapy for glaucoma, enhancing TM cell resilience and potentially lowering intraocular pressure, warranting further investigation.